WASHINGTON — Following nearly 2 years under the leadership of Commissioner Scott Gottlieb, MD, the FDA and its Acting Commissioner Norman E. Sharpless, MD, will continue to enact Gottlieb’s action plans in 2019 and keep an eye on potential challenges as the country moves toward the 2020 presidential election, a speaker said here.
Gottlieb resigned from his FDA position at the end of March, ending a term that saw the agency approve its first gene therapy, digital medicine initiative and digital therapeutic, Nancy Bradish Myers, Esq., of Catalyst Healthcare Consulting, said at the

Source link